Can I Take Green Tea Extract (EGCG) with AOD-9604? A Women's Guide to Safety, Interactions, and Dosing

What Are AOD-9604 and EGCG, and Why Are Women Combining Them?

AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone (amino acids 176-191). Researchers originally developed it at Monash University in the early 2000s as a targeted lipolytic agent. Unlike intact growth hormone, AOD-9604 does not stimulate IGF-1 production or affect blood glucose in the same way, which is one reason it attracted interest as a weight-management compound. It did not receive approval from the FDA as a pharmaceutical drug. It is currently available in the United States only through 503A compounding pharmacies as a research-use or off-label preparation, meaning it lacks the clinical-trial infrastructure of an approved medicine.

Green tea extract, standardized to its primary bioactive catechin epigallocatechin gallate (EGCG), is one of the most widely purchased supplements in the United States. Sales data from the American Botanical Council estimate that green tea products generated over $177 million in US retail sales in 2022. Women make up the majority of purchasers, often seeking metabolic, antioxidant, or weight-related benefits. The overlap with AOD-9604's intended use creates a predictable combination question.

The logic behind stacking them is understandable. AOD-9604 is thought to stimulate fat breakdown (lipolysis) and inhibit lipogenesis through a beta-3 adrenergic-like mechanism. EGCG inhibits catechol-O-methyltransferase (COMT), the enzyme that degrades norepinephrine, thereby prolonging adrenergic signaling in adipose tissue. On paper, both are prodding similar fat-oxidation pathways. The concern is not primarily a pharmacokinetic clash between the two compounds. It is about the independent hepatotoxicity risk of high-dose EGCG and how your individual liver clearance capacity, hormonal environment, and concurrent medications shape that risk.

How AOD-9604 Works in Women's Bodies

AOD-9604 binds to beta-3 adrenergic receptors in adipocytes, increasing cyclic AMP and activating hormone-sensitive lipase. Animal data from the original Monash group showed dose-dependent reduction in body fat in obese rodent models without changes in blood glucose or IGF-1 levels. Human trials were limited. The most-cited human safety study, Heffernan et al. (2001) published in the Journal of Endocrinology, found that a single subcutaneous dose of AOD-9604 at 25 mcg/kg increased fat oxidation acutely in overweight men without raising insulin or IGF-1. The trial enrolled predominantly men, which is a meaningful gap given that women have higher baseline adipose mass, different beta-adrenergic receptor density by fat depot, and that estrogen directly modulates beta-3 receptor expression in subcutaneous versus visceral adipose tissue.

Women in the perimenopausal transition, who experience rising visceral adiposity as estrogen declines, represent a population that providers are increasingly asking about peptides including AOD-9604. The existing human data does not answer whether dosing, efficacy, or safety differ by sex. That gap needs to be stated plainly.

How EGCG Works and Why the Dose Matters

EGCG inhibits COMT and also activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy sensing. At low-to-moderate doses from dietary green tea (roughly 50-100 mg EGCG per cup), these effects are mild and generally well-tolerated. Concentrated green tea extract supplements, however, can deliver 400-800 mg or more of EGCG per capsule, which is a physiologically and toxicologically different exposure. A 2018 systematic review by Mazzanti et al. In the European Journal of Clinical Pharmacology identified 78 case reports of green tea extract-associated liver injury, with onset typically within 3 months of starting a concentrated supplement and with women of reproductive age appearing disproportionately in the case series.

The Real Interaction: Pharmacokinetic vs. Pharmacodynamic

Understanding the nature of any interaction helps you make a practical decision. This combination involves both types.

Pharmacokinetic Interaction: EGCG's Effect on Drug-Metabolizing Enzymes

AOD-9604 is a peptide. Peptides are not meaningfully metabolized by CYP450 enzymes. They are hydrolyzed by peptidases in blood and tissue. This means EGCG's inhibition of CYP3A4, CYP2B6, and CYP1A2 does not directly alter AOD-9604 clearance. If you are taking any other medication alongside this combination, however, CYP inhibition by EGCG becomes highly relevant. Oral contraceptives, for example, are metabolized partly through CYP3A4, and EGCG-mediated inhibition of that enzyme could theoretically raise ethinyl estradiol exposure, increasing the risk of estrogen-related side effects.

EGCG also inhibits drug transporters including OATP1B1 and OATP1B3, as documented in a 2020 review in Drug Metabolism and Disposition. For women on thyroid hormone replacement (levothyroxine is an OATP substrate), this matters. Reduced transporter activity may alter thyroid hormone uptake, which is one reason timing separation of EGCG supplements from thyroid medications by at least 4 hours is often recommended in clinical practice.

Pharmacodynamic Interaction: Additive Adipose Effects and Shared Hepatic Stress

This is where the more direct concern lies. Both compounds ask the liver to do more work. Fat mobilized from adipocytes by AOD-9604 travels to the liver as free fatty acids. Simultaneously, EGCG at high doses can generate reactive oxygen species in hepatocytes, a mechanism proposed as the driver of its observed hepatotoxicity. Isbrucker et al. (2006) in Food and Chemical Toxicology showed that EGCG-induced mitochondrial dysfunction in hepatocyte cultures was concentration-dependent and worsened under fasting conditions, which matters because many women using AOD-9604 for fat loss are also practicing intermittent fasting.

A practical way to think about this combination is through what we call at WomanRx the Hepatic Load Framework: your liver's total oxidative and metabolic burden at any given time. That burden is the sum of every compound being processed, every fat flux event, and every pro-oxidant exposure. AOD-9604 increases fat flux to the liver. High-dose EGCG imposes oxidative stress on liver mitochondria. Alcohol, acetaminophen, hormonal contraceptives, and even vigorous fasting each add to that total load. The combination of AOD-9604 and high-dose EGCG is not uniquely toxic in the way a known drug-drug interaction is. Rather, it increases the total hepatic burden in a way that may push susceptible women past a tolerance threshold, particularly if additional factors are present.

Dose Guidance: How Much EGCG Is Actually the Problem?

Not all green tea supplements are equal. A standard cup of brewed green tea contains approximately 50-100 mg of EGCG. Most clinical studies showing metabolic benefits used 400-800 mg EGCG daily in supplement form. Liver-injury case reports cluster at doses at or above 800 mg per day, though rare cases have occurred at lower doses, particularly when supplements are taken on an empty stomach.

The US Pharmacopeia (USP) Dietary Supplement Expert Committee issued a cautionary monograph recommending that green tea extract products carry a label advisory about potential liver effects, particularly for fasted intake. If you are combining with AOD-9604, a reasonable upper bound based on available data is 400 mg EGCG per day, taken with food, not in a fasted state.

For AOD-9604 itself, typical compounded doses used in off-label clinical practice range from 250 mcg to 300 mcg subcutaneously once daily. No dose-ranging study in women exists in the peer-reviewed literature. This is an evidence gap you should discuss with the prescribing provider.

How Hormonal Status Changes Your Risk Profile

Reproductive Years (Ages 18-40)

Women in their reproductive years using oral contraceptives face a compounded CYP3A4 consideration. Oral contraceptives are themselves mild inhibitors of certain CYP enzymes, and adding EGCG's inhibition creates a layered effect. There is also a direct observation worth naming: a disproportionate share of green tea extract liver injury reports involve women of reproductive age, suggesting either hormonal susceptibility, higher supplement use rates in this demographic, or both. The mechanism is not fully established, but estrogen's role in bile acid transport and hepatic oxidative stress handling is a plausible contributor.

Perimenopause and Menopause

As estrogen declines during the menopausal transition, visceral adipose tissue increases and hepatic fat deposition becomes more common. Non-alcoholic fatty liver disease (NAFLD) prevalence rises sharply in postmenopausal women compared to premenopausal women of similar BMI, a pattern documented in a 2020 meta-analysis in Menopause. A liver with early steatosis may be less tolerant of the combined fat-flux increase from AOD-9604 and the oxidative stress from high-dose EGCG. For perimenopausal and postmenopausal women interested in this combination, baseline liver function testing and an abdominal ultrasound to rule out hepatic steatosis are reasonable before starting.

PCOS

Women with PCOS have elevated rates of insulin resistance, hyperandrogenism, and NAFLD (estimated at 30-70% prevalence depending on diagnostic criteria). EGCG's insulin-sensitizing effects via AMPK activation have been studied specifically in PCOS. A 2016 randomized controlled trial by Liu et al. In the Journal of Nutritional Biochemistry found that 800 mg EGCG daily for 12 weeks improved fasting insulin and testosterone in women with PCOS compared to placebo. Whether AOD-9604 adds benefit, or risk, in this population is completely unstudied. Given the high baseline NAFLD prevalence in PCOS, liver monitoring is especially important.

Trying to Conceive

If you are actively trying to conceive, neither AOD-9604 nor high-dose green tea extract should be part of your routine. Both are unproven in this context and carry theoretical reproductive risks discussed in the pregnancy section below.

Pregnancy and Lactation Safety

AOD-9604 is contraindicated in pregnancy. No human safety data exist for use during gestation. The compound is a growth hormone fragment, and growth hormone signaling pathways play roles in placental development and fetal growth regulation that are not fully characterized. Animal embryotoxicity studies have not been published in peer-reviewed literature for this specific peptide. The standard clinical position for any compounded, non-approved peptide is to stop use when pregnancy is confirmed or planned. Because AOD-9604 is typically administered by injection and prescriptions are controlled through the compounding pharmacy, stopping is straightforward. No specific wash-out period is established, but given its short peptide half-life (estimated hours based on related GH fragments), the peptide clears rapidly.

High-dose green tea extract carries its own pregnancy concerns. EGCG inhibits folate transport. A study by Kalmbach et al. In the American Journal of Clinical Nutrition demonstrated that high EGCG concentrations reduced cellular folate uptake in vitro, raising concern about neural tube defect risk if high-dose green tea extract supplements are used periconceptionally. Brewed green tea in normal dietary amounts (1-2 cups daily) is generally considered safe in pregnancy, but concentrated extract supplements are not recommended.

Lactation: EGCG is present in breast milk at low concentrations following dietary green tea consumption. The clinical significance is unclear, but concentrated green tea extract supplements are not recommended during breastfeeding given the hepatotoxicity risk to the mother and uncertain neonatal exposure. AOD-9604 transfer into breast milk has not been studied. No breastfeeding safety data exist. Use during lactation is not advised.

Contraception requirement: If you are using AOD-9604 for fat loss and are of reproductive potential, reliable contraception is appropriate given the absence of pregnancy safety data. Your prescriber should document this conversation.

Who This Combination Is Right For, and Who Should Avoid It

Potentially Appropriate (with monitoring)

• Women post-menopause with no liver disease history, using low-dose green tea extract (200-400 mg EGCG daily with food), who have confirmed normal baseline liver enzymes and have discussed AOD-9604 with an experienced prescriber
• Women in their 30s-40s not using hormonal contraceptives, with normal liver function, who keep EGCG below 400 mg per day and have a provider monitoring labs

Use Requires Extra Caution

• Women on oral contraceptives (CYP3A4 interaction adds complexity)
• Women with PCOS, given high baseline NAFLD prevalence
• Women on thyroid hormone replacement (OATP transporter inhibition by EGCG; separate doses by at least 4 hours)
• Perimenopausal women with any known hepatic steatosis

Avoid This Combination

• Pregnant women or those actively trying to conceive
• Breastfeeding women
• Women with any active liver disease, elevated transaminases at baseline, or history of drug-induced liver injury
• Women taking other CYP3A4-metabolized medications where fluctuation is clinically significant (anticoagulants, immunosuppressants, certain antiepileptics)
• Women using high-dose green tea extract (above 800 mg EGCG daily) in a fasted state

Practical Monitoring Protocol

If you and your provider decide to proceed with both compounds, a structured monitoring plan reduces risk meaningfully.

Before starting:

• Complete metabolic panel including ALT, AST, alkaline phosphatase, and bilirubin
• Fasting lipid panel (AOD-9604 is intended to alter lipid metabolism)
• Review all concurrent medications for CYP3A4 interactions with EGCG

At 6 weeks:

• Repeat ALT and AST. A rise to more than twice the upper limit of normal should prompt stopping green tea extract immediately and repeating labs in 2 weeks.

Ongoing:

• Do not take green tea extract on an empty stomach. Take it with the largest meal of the day.
• If you experience nausea, right-upper-quadrant discomfort, dark urine, or jaundice, stop both compounds and seek evaluation the same day.
• Drug-induced liver injury from supplements typically resolves within weeks of stopping the offending agent, but early identification matters.

Dose separation: Because EGCG's peak plasma concentration occurs roughly 1-2 hours after an oral dose, and AOD-9604 is administered subcutaneously with a different absorption profile, timing separation is not a primary concern for this specific pair. The separation advice applies to other drugs you may be taking concurrently.

What the Evidence Gap Means for You

This combination has zero direct clinical trial data. Zero. What exists is mechanistic plausibility, individual compound safety profiles, case reports of harm from one component (EGCG), and limited human efficacy data for the other (AOD-9604) mostly from male subjects. Women's bodies process fat, hormones, and hepatic stress differently from men's at every life stage. Any risk-benefit conversation you have about this combination should name that gap explicitly rather than extrapolate from data that was not collected in women.

The honest clinical picture is this: if you are a healthy, non-pregnant, non-breastfeeding woman with normal liver enzymes who wants to use a low-to-moderate dose of green tea extract (200-400 mg EGCG) alongside a physician-supervised AOD-9604 protocol, the theoretical interaction risk is manageable with monitoring. If any of the caution or avoid criteria above apply to you, the risk-benefit math changes substantially.